Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
about
The glycolipid exoantigen derived from Chlamydia muridarum activates invariant natural killer T cells.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldExploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies.Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challengeMicroparticles as vaccine adjuvants and delivery systems.The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cellsDelivery of Chlamydia vaccines.Microparticles for oral delivery of vaccines.Characterization of anti-anti-idiotypic antibodies that bind antigen and an anti-idiotype.Bioadhesive delivery systems for mucosal vaccine delivery.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae.Cost-effectiveness of screening for genital Chlamydia trachomatis.Aging and immunoglobulin isotype patterns in oral tolerance.Antitumor effect of the idiotypic cascade induced by an antibody encapsulated in poly(d,l-lactide-co-glycolide) microspheres.
P2860
Q33577448-E2E2C1A0-68E9-4CA0-88FF-7A3C0EFE2987Q33894321-E98A0F5F-E0C9-4669-AA5C-6EA40D6A9834Q33901818-C642871B-BEF6-4A0F-BA88-E481CFF711FCQ34006511-8FE269B8-6CD0-4547-BC9E-2B36C099FA10Q34009341-188CD403-6B75-4E0F-AD60-30F6E6E22388Q35192199-1A6BB06C-8914-4A45-BAB9-A44E022C7C42Q35828850-3E61107C-246E-4E0D-AEFF-BD2B4691840EQ36316798-8920AC3D-5ED0-4107-8A7A-565E32DBCA2BQ36316809-EFBB5331-6044-4DC7-8B38-2E72EF597ACAQ36555675-7638E98C-0A27-4181-A3CF-D5214768922CQ37805519-2C704097-5CF1-466D-800A-2785B7DF46C5Q37812128-9241EAF3-2B90-4EC7-9C1D-956E60A4EE58Q37834084-9DF8E968-3BEA-4423-9BBC-EB06614CFCDBQ37862860-3F4694F7-9585-41F3-90C4-56B62A89882EQ37873013-552A891F-87F4-45BB-9F12-BABEF45F6FA0Q47758508-39F09748-14D3-4175-955A-C00FF017DBB8Q55154679-AE69FEAD-753D-42C4-BD03-179DBD4B8E4A
P2860
Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral immunization with an anti ...... lamydia trachomatis infection.
@en
Oral immunization with an anti ...... lamydia trachomatis infection.
@nl
type
label
Oral immunization with an anti ...... lamydia trachomatis infection.
@en
Oral immunization with an anti ...... lamydia trachomatis infection.
@nl
prefLabel
Oral immunization with an anti ...... lamydia trachomatis infection.
@en
Oral immunization with an anti ...... lamydia trachomatis infection.
@nl
P2093
P2860
P921
P356
P1433
P1476
Oral immunization with an anti ...... lamydia trachomatis infection.
@en
P2093
MacDonald AB
Prendergast RA
Saltzman WM
Whittum-Hudson JA
P2860
P2888
P304
P356
10.1038/NM1096-1116
P407
P577
1996-10-01T00:00:00Z